First Tracks Biotherapeutics (TRAX) — Tangible Net Worth Ratio
First Tracks Biotherapeutics (TRAX) has a Tangible Net Worth Ratio of 100.0% as of June 2026. This metric is calculated by deducting intangible assets ($0.00) from net assets ($168.80 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore net asset momentum of First Tracks Biotherapeutics to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
First Tracks Biotherapeutics Tangible Net Worth Ratio (2023–2025)
This chart shows how First Tracks Biotherapeutics's Tangible Net Worth Ratio has changed across 3 annual periods from 2023 to 2025. As of June 2026, the ratio stands at 100.0%, reflecting net assets of $168.80 Million with intangible assets of $0.00 USD. Check TRAX capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Annual Tangible Net Worth Ratio for First Tracks Biotherapeutics (2023–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for First Tracks Biotherapeutics from 2023 to 2025, covering 3 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see First Tracks Biotherapeutics market capitalisation.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 100.0% | $287.49 Million | $0.00 | $330.55 Million | ▲ +0.0 pp |
| 2024 | 100.0% | $391.60 Million | $0.00 | $441.89 Million | ▲ +0.0 pp |
| 2023 | 100.0% | $409.85 Million | $0.00 | $444.11 Million | — |